510(k) Report

PMA · Approved

Approved

Guardant360® Liquid CDx

P250027PMAApproved May 19, 2026292-day reviewClass III

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Guardant Health, Inc. · PQP Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System

Approved on May 19, 2026 through premarket approval, which rests on the device’s own clinical evidence after a 292-day review.

Decided
May 19, 2026
Review
292 days
Class
Class III
Product code
PQP
Recalls
None

PMA approvals rest on their own clinical evidence and do not claim a predicate, so this family tree starts here.

P250027 has 1 supplement since 2026: changes to the approved device, its labelling or its manufacturing, each approved separately.

PMA supplements approved per year

2026: 1
2026high 1 (2026) · low 0 (2027)2027
View FIG. 1 as a table
YearSupplements approved
20261
FIG. 1 — Supplements to P250027, 2026–2026Source: FDA PMA database

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA PMA database (decision fields and supplements), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PQP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

Does it have a predicate?

PMA decisions do not claim a predicate device.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All PQP devices

PQP Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.

FDA decisions per year · PQP

37so far in 2026, the most since 2007

2016: 12017: 62018: 152019: 212020: 252021: 172022: 332023: 342024: 342025: 212026 (partial year): 37
2007high 37 (2026) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PQP

Too few PQP 510(k)s in any year since 2007 to give a median.

Recalls per year · PQP

3so far in 2026, the most since 2007

2018: 12019: 12022: 22026 (partial year): 3
2007high 3 (2026) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · PQP

2in 2023

2017: 12018: 12020: 12021: 12022: 12023: 2
2007high 2 (2023) · low 0 (2007)2025

MAUDE reports naming product code PQP, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20161—00
20176—01
201815—11
201921—10
202025—01
202117—01
202233—21
202334—02
202434—00
202521—00
202637—3—
Cite this page

510(k) Report. “P250027: Guardant360® Liquid CDx.” Lineage record from FDA PMA data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/P250027

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded Oct 30, 2026
  • Page last updated Nov 3, 2026